Drug Trial Radar · NCT07465718
Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
38
Planned (sponsor's estimate)
Start
Sep 3, 2026
Primary completion
Feb 2028
Study completion Feb 2028
Sponsor
- Lead sponsor
- OrphalanIndustry
- Sponsor type
- Industry
- First posted
- Mar 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 8 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if a new trientine tetrahydrochloride (TETA 4HCl) formulation administered once a day compared to d-Penicillamine (DPA) as a first line treatment for people living with Wilson's disease (WD) is effective and safe. The study is enrolling children aged 8 years and older weighing at least 55 lb (25 kg) and adults with a recent diagnosis of WD. People recently diagnosed with WD, may be eligible for the study if they have either not started copper chelating treatment (such as DPA or trientine) or have been taking zinc salts for less than 28 days. Participants will be randomly allocated (like tossing a coin) to receive either DPA or TETA 4HCL for 48 weeks. During this time period participants will have up to 12 visits for health checks and assessments including blood and urine testing. In addition, at some visits participants may be asked to complete questionnaires on treatment satisfaction, and overall well-being.
Conditions
- Wilson's Disease
Interventions
TETA 4HCl formulationDrug
The new formulation of TETA 4HCl will be administered once a day. Each film-coated tablet is scored to enable halving, if required. Randomized participants are planned to receive TETA 4HCl for the 48-week post-randomization period.
D-PenicillamineDrug
Standard of care DPA is to be used, per the sites and treating physician's usual practice. To be administered in accordance with the product labelling and/or the institutions treatment practice guidelines. Randomised participants are planned to receive DPA for the 48-week post-randomization period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute value of serum NCC at Week 48 assessed using the NCC-speciation assay (serum NCC-Sp)Time frame: Week 48
Locations
10 sites in 4 countries. Site status is shown where the registry gives one.
University of Colorado Anschutz School of Medicine
Denver, Colorado · Recruiting
Yale University School of Medicine
New Haven, Connecticut · Not yet recruiting
University of Michigan Medical Centre
Ann Arbor, Michigan · Recruiting
Beijing YouAn Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Beijing Friendship Hospital,Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhengjiang Province, China · Recruiting
PIMS Hospital
Islamabad, Pakistan · Not yet recruiting
Shifa International Hospital
Islamabad, Pakistan · Not yet recruiting
Children's Hospital & Institute of Child Health
Lahore, Pakistan · Not yet recruiting
King Faisal Specialist Hospital and Research Center
Riyadh, Saudi Arabia · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.